Catheter Precision (VTAK) Proxy Filing summary

Executive summary

• Annual meeting scheduled for July 25, 2025, will be held virtually; stockholders must register in advance to attend and vote online.

• Six key proposals will be presented: election of one director, approval of share issuances related to warrants and preferred stock, a reverse stock split, and auditor ratification.

• Board recommends voting in favor of all proposals; voting can be done online, by phone, or by mail.

Voting matters and shareholder proposals

• Proposal 1: Elect Martin Colombatto as Class I director for a three-year term.

• Proposal 2: Approve issuance of up to 4,285,716 shares upon exercise of Series L Warrants.

• Proposal 3: Approve issuance of up to 8,574,000 shares upon conversion of Series B Convertible Preferred Stock.

• Proposal 4: Approve issuance of up to 257,143 shares upon exercise of 2025 Placement Agent Warrants.

• Proposal 5: Approve a reverse stock split at a ratio between 1-for-5 and 1-for-19, at Board discretion.

• Proposal 6: Ratify WithumSmith + Brown, PC as independent auditor for fiscal year 2025.

• Board recommends a vote “FOR” on all proposals.

Board of directors and corporate governance

• Board consists of four members, three of whom are independent under NYSE American standards.

• Directors serve staggered three-year terms; current nominee is Martin Colombatto.

• Board committees: audit, compensation, and nominating/corporate governance, all with independent members.

• Board leadership structure includes an Executive Chairman who is also CEO; independent directors meet separately.

• Board evaluates director nominees based on ethics, experience, diversity, and independence.